Magstone Law provided legal services for Arnatar Therapeutics' $50 million Series A financing.

2024-08-04 03:59:51

Magstone Law is pleased to announce that it recently served as legal counsel for Angtuo's successful completion of a $50 million Series A financing round. This pivotal investment will accelerate Angtuo's groundbreaking antisense therapies, advance its clinical trials, and establish a strategic presence in the Chinese market.

This financing round was co-led by Sironax and Benovo Capital, with participation from prominent investment institutions such as Huajin Capital, Gaorong Capital, Jifeng Capital, Lianxin Capital, Yijing Capital, and Legend Star, the early-stage investment platform under Legend Holdings.

Founded in 2022 and headquartered in San Diego, California, Angtuo is dedicated to developing drugs based on antisense nucleic acid technology. This innovative therapy leverages advanced small interfering RNA (siRNA) and antisense oligonucleotide (ASO) platforms to modulate gene expression, aiming to treat both common and rare diseases, particularly those affecting the liver and extrahepatic organs.

Led by distinguished scientists, Angtuo's founding team includes Dr. Xuehai Liang, a renowned scientist formerly with Ionis Pharmaceuticals, and Dr. Yanfeng Wang, a seasoned executive with experience at Merck, Novartis, and Ionis. Their combined expertise underscores Angtuo's potential in the biotechnology industry.